Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
other
Intercell AG and Statens Serum Institut join forces with Aeras Global TB Vaccine Foundation for novel Tuberculosis Vaccine

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
27.06.2005
Vienna / Copenhagen / Bethesda, June 27, 2005 - Intercell AG and
Statens Serum Institut (SSI) announced today that their joint project
for the development of a new prophylactic tuberculosis vaccine has
gained the support of the Aeras Global TB Vaccine Foundation. Aeras,
an organization funded by the Bill and Melinda Gates Foundation,
specializes in the development of novel TB vaccines with the aim of
controlling the disease in developing countries.
Under the terms of the agreement, Aeras will fund the development of
the vaccine and subsequent clinical trials. In return, Aeras will be
given a sublicense for the future TB vaccine for a number of
developing countries with an urgent medical need and very low living
standards. For the rest of the world Intercell and SSI will retain
their joint marketing and profit-sharing rights.  The product
candidate combines Intercell's proprietary synthetic adjuvant IC31TM
with SSI's recombinant tuberculosis antigens. The expanded
collaboration continues to evaluate further tuberculosis antigens in
combination with Intercell's novel adjuvant technology.
Intercell’s CEO, Alexander von Gabain, commented: "We are delighted
that our collaboration with Statens Serum Institut on a novel
tuberculosis vaccine has now obtained the support of the renowned
Aeras Foundation. The new partner will bring substantial funding as
well as first-class scientific and pharmaceutical expertise to this
project. Furthermore we also like to thank both the Austrian Ministry
for Economy and Labour as well as the Vienna Business Agency for
supporting this promising project with R&D grants."
About Tuberculosis Tuberculosis kills two million people each year
and the disease is predicted to make a dramatic return to
industrialized countries. It is estimated that between 2002 and 2020,
approximately one billion people will be newly infected, over 150
million people will get sick, and 36 million will die of TB - if
control is not further strengthened. The current vaccine - BCG - is
one of the oldest presently in use throughout the world and has a
limited efficacy profile.
About Intercell AG Intercell AG is a fast growing biotechnology
company with a clear strategy and focus on the design and development
of novel vaccines for prophylaxis and treatment of diseases with
substantial unaddressed medical need. The Company’s unique position
is based on the combination of antigens and immunizers (adjuvants)
derived from its proprietary technology platforms and its in-house
GMP manufacturing facilities. Intercell’s technology has been
endorsed by collaborative agreements with a number of global
pharmaceutical companies, including Sanofi Aventis, Merck&Co., Inc.,
SciGen Ltd. and the Statens Serum Institut. The Company has a broad
development pipeline with a vaccine for Japanese Encephalitis about
to enter Phase III, a vaccine for Hepatitis C undergoing Phase II
trials, and five products focused on infectious diseases in the
pre-clinical phase. Intercell is listed on the Vienna stock exchange
under the symbol "ICLL". For more information please visit:
www.intercell.com
end of announcement                               euro adhoc 27.06.2005 08:00:00

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN:
Börsen: Wiener Börse AG

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG